Genomics Reporting Implementation Guide
2.0.0 - trial-use

This page is part of the Genetic Reporting Implementation Guide (v2.0.0: STU 2) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Example Task: MedicationRecommendationExample1

Generated Narrative

Resource "MedicationRecommendationExample1"

Profile: Medication Recommendation

status: requested

intent: proposal

code: Consider alternative medication (LOINC#LA26421-0)

description: Patients positive for this allele should not be treated with CBZ, unless the benefits clearly outweigh the risk. Therapy should be discontinued immediately if symptoms of SJS or TEN develop. Alternative medication should be used as first line therapy. Consideration in the choice for alternative medications should be given to potential cross-reactivity with structurally similar aromatic antiepileptic drugs such as oxcarbazepine, phenytoin, fosphenytoin and lamotrigine, which can also moderately increase risk for SJS/TEN in association with HLA-B*15:02 positivity.

for: Patient/CGPatientExample01 " EVERYMAN"

reasonReference: Observation/TherapeuticImplicationExample1